Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REaCT-BTA: 4-weekly vs 12-weekly Bone-targeted Agents
NCT02721433Phase 4Completed
- Sponsor
- Ottawa Hospital Research Institute
- Start
- Aug 2016
- Primary completion
- Sep 2019
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of pamidronate, denosumab, zoledronate in bone metastasis, sponsored by Ottawa Hospital Research Institute. Started Aug 2016; status: completed.
02
Drugs
pamidronatedenosumabzoledronate
03
Conditions
bone metastasis
Beyond the preview
Go deeper on NCT02721433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02721433.